# Saypha® VOLUME Lidocaine for Midface Augmentation

> **NCT05386030** · PHASE3 · COMPLETED · sponsor: **Croma-Pharma GmbH** · enrollment: 562 (actual)

## Conditions studied

- Moderate to Severe Midface Volume Deficit

## Interventions

- **COMBINATION_PRODUCT:** saypha® VOLUME Lidocaine
- **COMBINATION_PRODUCT:** Juvéderm® Voluma™ XC

## Key facts

- **NCT ID:** NCT05386030
- **Lead sponsor:** Croma-Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-16
- **Primary completion:** 2023-10-04
- **Final completion:** 2024-12-11
- **Target enrollment:** 562 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386030, "Saypha® VOLUME Lidocaine for Midface Augmentation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05386030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*